Published in J Cereb Blood Flow Metab on May 17, 2006
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol (2010) 1.24
In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer. J Nucl Med (2010) 1.19
Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. Biol Psychiatry (2013) 1.07
Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET. J Nucl Med (2008) 1.03
Tracer kinetic modeling of [(11)C]AFM, a new PET imaging agent for the serotonin transporter. J Cereb Blood Flow Metab (2013) 1.02
In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688. J Cereb Blood Flow Metab (2011) 0.94
SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med (2011) 0.91
Modeling considerations for in vivo quantification of the dopamine transporter using [(11)C]PE2I and positron emission tomography. J Cereb Blood Flow Metab (2009) 0.89
In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. Eur J Nucl Med Mol Imaging (2011) 0.89
Empirical Bayesian estimation in graphical analysis: a voxel-based approach for the determination of the volume of distribution in PET studies. Nucl Med Biol (2010) 0.85
Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans. Eur J Nucl Med Mol Imaging (2012) 0.83
Prediction of selective serotonin reuptake inhibitor response using diffusion-weighted MRI. Front Psychiatry (2013) 0.83
Reference region approaches in PET: a comparative study on multiple radioligands. J Cereb Blood Flow Metab (2013) 0.81
Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242. Neuroimage (2014) 0.80
Model-free quantification of dynamic PET data using nonparametric deconvolution. J Cereb Blood Flow Metab (2015) 0.78
Test-retest variability of adenosine A2A binding in the human brain with (11)C-TMSX and PET. EJNMMI Res (2014) 0.77
Positron emission tomography quantification of serotonin transporter binding in medication-free bipolar disorder. Synapse (2015) 0.75
Test-retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943. Eur J Nucl Med Mol Imaging (2014) 0.75
Relationship of the serotonin transporter gene promoter polymorphism (5-HTTLPR) genotype and serotonin transporter binding to neural processing of negative emotional stimuli. J Affect Disord (2015) 0.75
Quantifying serotonin transporters by PET with [11C]-DASB before and after interferon-α treatment. Synapse (2014) 0.75
In vivo quantification of the [(11)C]DASB binding in the normal canine brain using positron emission tomography. BMC Vet Res (2015) 0.75
A positron emission tomography study of the serotonergic system in relation to anxiety in depression. Eur Neuropsychopharmacol (2017) 0.75
A global optimisation method for robust affine registration of brain images. Med Image Anal (2001) 27.87
Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab (1990) 6.62
A molecular and cellular theory of depression. Arch Gen Psychiatry (1997) 6.10
Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab (2001) 3.31
Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med (2000) 2.26
Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry (2005) 2.16
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (1998) 2.03
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry (2004) 2.00
Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry (2006) 1.96
Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome. Psychiatry Res (1997) 1.85
Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. J Cereb Blood Flow Metab (2000) 1.77
Estimation of kinetic parameters in graphical analysis of PET imaging data. Stat Med (2003) 1.56
Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab (2002) 1.56
Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry (2001) 1.47
Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem (2000) 1.44
Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med (2000) 1.38
Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med (2004) 1.35
Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab (2001) 1.32
Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology (1999) 1.30
Estimation in regression models with externally estimated parameters. Biostatistics (2005) 1.29
Metabolite considerations in the in vivo quantification of serotonin transporters using 11C-DASB and PET in humans. J Nucl Med (2006) 1.17
Determination of volume of distribution using likelihood estimation in graphical analysis: elimination of estimation bias. J Cereb Blood Flow Metab (2003) 1.14
Automatic segmentation of the brain and intracranial cerebrospinal fluid in T1-weighted volume MRI scans of the head, and its application to serial cerebral and intracranial volumetry. Magn Reson Med (2003) 1.11
In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol (2002) 1.08
An interactive procedure for extracting features of the brain from magnetic resonance images: the lobes. Hum Brain Mapp (1997) 1.02
Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry (2003) 0.96
Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse (2005) 0.95
Biodistribution and radiation dosimetry of [11C]DASB in baboons. Nucl Med Biol (2004) 0.92
Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage (2009) 11.90
The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry (2011) 9.18
Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry (2007) 6.80
Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry (2007) 6.35
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell (2008) 5.93
Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry (2006) 3.44
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry (2012) 3.29
A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell (2009) 3.28
The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry (2005) 3.24
Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry (2012) 3.24
Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry (2004) 3.19
Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron (2002) 3.06
Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry (2011) 3.04
Familial pathways to early-onset suicide attempt: risk for suicidal behavior in offspring of mood-disordered suicide attempters. Arch Gen Psychiatry (2002) 2.76
Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry (2009) 2.76
Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry (2007) 2.52
Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science (2006) 2.49
Depression in bipolar disorder versus major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar Disord (2012) 2.47
Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry (2013) 2.46
Familial pathways to early-onset suicidal behavior: familial and individual antecedents of suicidal behavior. Am J Psychiatry (2007) 2.43
Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C Semin Med Genet (2005) 2.43
The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry (2013) 2.39
Evaluation of volume-based and surface-based brain image registration methods. Neuroimage (2010) 2.38
Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med (2010) 2.32
Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry (2006) 2.31
Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. J Neurosci (2011) 2.21
Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry (2005) 2.16
Instability of symptoms in recurrent major depression: a prospective study. Am J Psychiatry (2004) 2.12
Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest (2006) 2.08
Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol Psychiatry (2005) 2.06
Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? Drug Saf (2011) 2.05
Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry (2005) 2.03
11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med (2009) 1.99
Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry (2009) 1.98
Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry (2006) 1.96
Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry (2002) 1.95
Issues for DSM-V: suicidal behavior as a separate diagnosis on a separate axis. Am J Psychiatry (2008) 1.92
Diagnostic stability of psychiatric disorders in clinical practice. Br J Psychiatry (2007) 1.88
Simultaneous dual-radionuclide myocardial perfusion imaging with a solid-state dedicated cardiac camera. Eur J Nucl Med Mol Imaging (2010) 1.86
Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology (2004) 1.82
Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry (2011) 1.81
Posttraumatic stress disorder comorbid with major depression: factors mediating the association with suicidal behavior. Am J Psychiatry (2005) 1.78
Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry (2007) 1.78
Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Arch Gen Psychiatry (2003) 1.78
Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry (2005) 1.77
Testosterone levels in suicide attempters with bipolar disorder. J Psychiatr Res (2012) 1.72
Antidepressants and suicide risk in the United States, 1985-1999. J Clin Psychiatry (2004) 1.72
Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res (2002) 1.71
Are BPI and BPII suicide attempters distinct neuropsychologically? J Affect Disord (2006) 1.60
The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2011) 1.57
Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry (2003) 1.55
Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab (2005) 1.55
The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry (2006) 1.52
Serotonin brain circuits involved in major depression and suicide. Prog Brain Res (2002) 1.52
Religious affiliation and suicide attempt. Am J Psychiatry (2004) 1.51
An association between a functional polymorphism in the monoamine oxidase a gene promoter, impulsive traits and early abuse experiences. Neuropsychopharmacology (2004) 1.49
Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology (2006) 1.45
Sex differences in clinical predictors of suicidal acts after major depression: a prospective study. Am J Psychiatry (2007) 1.45
Effect of exposure to suicidal behavior on suicide attempt in a high-risk sample of offspring of depressed parents. J Am Acad Child Adolesc Psychiatry (2010) 1.45
Post-approval drug safety surveillance. Annu Rev Public Health (2010) 1.43
Suicide attempts and impulsivity. Eur Arch Psychiatry Clin Neurosci (2004) 1.43
A suicide prevention program in a region with a very high suicide rate. Arch Gen Psychiatry (2007) 1.42
Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J Psychiatr Res (2007) 1.40
Internally displaced "victims of armed conflict" in Colombia: the trajectory and trauma signature of forced migration. Curr Psychiatry Rep (2014) 1.39
Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Res (2005) 1.36
Sex genes for genomic analysis in human brain: internal controls for comparison of probe level data extraction. BMC Bioinformatics (2003) 1.36
Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. J Neurochem (2003) 1.36
Can biological tests assist prediction of suicide in mood disorders? Int J Neuropsychopharmacol (2005) 1.35
Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphe nuclei: major depression and suicide. Neuropsychopharmacology (2006) 1.35
Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry (2010) 1.33
Effect of acute alcohol use on the lethality of suicide attempts in patients with mood disorders. J Psychiatr Res (2009) 1.33
Association of comorbid posttraumatic stress disorder and major depression with greater risk for suicidal behavior. Am J Psychiatry (2003) 1.32
Peripubertal suicide attempts in offspring of suicide attempters with siblings concordant for suicidal behavior. Am J Psychiatry (2003) 1.32
Is impulsivity a link between childhood abuse and suicide? Compr Psychiatry (2009) 1.31
Genetics of the serotonergic system in suicidal behavior. J Psychiatr Res (2003) 1.31
Classification trees distinguish suicide attempters in major psychiatric disorders: a model of clinical decision making. J Clin Psychiatry (2008) 1.31
Attention deficit in depressed suicide attempters. Psychiatry Res (2008) 1.30
Depressive symptoms and antidepressant use in a random community sample of ethnically diverse, urban elder persons. J Affect Disord (2007) 1.29